

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Piramal Life Sciences Limited	06/15/2012
RECEIVING PARTY DATA	
Name:	Piramal Healthcare Limited
Street Address:	Piramal Tower, Ganapatrao Kadam Marg
Internal Address:	Lower Parel
City:	Mumbai
State/Country:	INDIA
Postal Code:	400 013
PROPERTY NUMBERS Total: 13	
Property Type	Number
Application Number:	12305815
Application Number:	13222662
Application Number:	12441958
Application Number:	12600019
Application Number:	13092245
Application Number:	13157075
Application Number:	13026503
Application Number:	12441891
Patent Number:	7271193
Patent Number:	7884127
Patent Number:	7915301
Patent Number:	7951961
Patent Number:	8030324
CORRESPONDENCE DATA	

501984611

PATENT
 REEL: 028527 FRAME: 0874

CH \$520.00 12305815

Fax Number: (212)588-0500
Phone: 2125880800
Email: dgamache@flhlaw.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: Frommer Lawrence & Haug LLP
Address Line 1: 745 Fifth Avenue
Address Line 4: New York, NEW YORK 10151

ATTORNEY DOCKET NUMBER:	516745-1000
-------------------------	-------------

NAME OF SUBMITTER:	Danielle Gamache
--------------------	------------------

Total Attachments: 96

source=01127629#page1.tif
source=01127629#page2.tif
source=01127629#page3.tif
source=01127629#page4.tif
source=01127629#page5.tif
source=01127629#page6.tif
source=01127629#page7.tif
source=01127629#page8.tif
source=01127629#page9.tif
source=01127629#page10.tif
source=01127629#page11.tif
source=01127629#page12.tif
source=01127629#page13.tif
source=01127629#page14.tif
source=01127629#page15.tif
source=01127629#page16.tif
source=01127629#page17.tif
source=01127629#page18.tif
source=01127629#page19.tif
source=01127629#page20.tif
source=01127629#page21.tif
source=01127629#page22.tif
source=01127629#page23.tif
source=01127629#page24.tif
source=01127629#page25.tif
source=01127629#page26.tif
source=01127629#page27.tif
source=01127629#page28.tif
source=01127629#page29.tif
source=01127629#page30.tif
source=01127629#page31.tif
source=01127629#page32.tif
source=01127629#page33.tif
source=01127629#page34.tif
source=01127629#page35.tif
source=01127629#page36.tif
source=01127629#page37.tif
source=01127629#page38.tif
source=01127629#page39.tif

source=01127629#page40.tif
source=01127629#page41.tif
source=01127629#page42.tif
source=01127629#page43.tif
source=01127629#page44.tif
source=01127629#page45.tif
source=01127629#page46.tif
source=01127629#page47.tif
source=01127629#page48.tif
source=01127629#page49.tif
source=01127629#page50.tif
source=01127629#page51.tif
source=01127629#page52.tif
source=01127629#page53.tif
source=01127629#page54.tif
source=01127629#page55.tif
source=01127629#page56.tif
source=01127629#page57.tif
source=01127629#page58.tif
source=01127629#page59.tif
source=01127629#page60.tif
source=01127629#page61.tif
source=01127629#page62.tif
source=01127629#page63.tif
source=01127629#page64.tif
source=01127629#page65.tif
source=01127629#page66.tif
source=01127629#page67.tif
source=01127629#page68.tif
source=01127629#page69.tif
source=01127629#page70.tif
source=01127629#page71.tif
source=01127629#page72.tif
source=01127629#page73.tif
source=01127629#page74.tif
source=01127629#page75.tif
source=01127629#page76.tif
source=01127629#page77.tif
source=01127629#page78.tif
source=01127629#page79.tif
source=01127629#page80.tif
source=01127629#page81.tif
source=01127629#page82.tif
source=01127629#page83.tif
source=01127629#page84.tif
source=01127629#page85.tif
source=01127629#page86.tif
source=01127629#page87.tif
source=01127629#page88.tif
source=01127629#page89.tif
source=01127629#page90.tif
source=01127629#page91.tif
source=01127629#page92.tif
source=01127629#page93.tif
source=01127629#page94.tif

source=01127629#page95.tif

source=01127629#page96.tif


भारतीय गैर न्यायिक

एक सौ रुपये

Rs. 100

₹. 100

ONE
HUNDRED RUPEES



सत्यमेव जयते

भारत INDIA
INDIA NON JUDICIAL

महाराष्ट्र MAHARASHTRA

सोमला स्टेशनरी मार्ग-3 MAY 2012 नं. 103.

FP 609303

General Stamp Office, Mumbai
L.S.V. No. 207

27 APR 2012

Proper Officer

ऐसप्लान्ड मंगल काला बांडा मार्ग-23.

परवानाधारक मुद्रांक विक्रेता

Piramal Healthcare Limited

1, Nirjon Complex,

01223

Off. Western Express Highway,

M/s./Mrs./Mr.

Gurugram (East) Mumbai-400 063.

यांना न्यायोत्तरे मुद्रांक पत्र विक्रीला.

परवानाधारक मुद्रांक विक्रेता.

SHRI. K. R. MADG.

DEED OF ASSIGNMENT

THIS DEED OF ASSIGNMENT made and entered into on this 15th day of June in the year Two Thousand Twelve between


PIRAMAL LIFE SCIENCES LIMITED, of Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India hereinafter referred to as the "ASSIGNOR" (which expression shall, unless repugnant to the context meaning thereof, be deemed to include its heirs, successors and assignors) of the ONE PART

AND

PIRAMAL HEALTHCARE LIMITED, of Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India hereinafter referred to as "ASSIGNEE" (which expression shall, unless repugnant to the context meaning thereof, be deemed to include its heirs, successors and assigns) of the OTHER PART

PATENT

REEL: 028527 FRAME: 0878



सोमका स्टांपनरी मार्ग, शां न २, १४४, गुलाब रोड,
ऐतकावडे मंगल नगर, मुंबई ४०० ०६३.
परवानाधारक मुद्रांक विक्रेता

FP 609304

परवाना क्रमांक नं. २०७
ब्रम्कि 1224 Piramal Healthcare Limited
M/s / Mrs / Mr I. Nirjon Complex,
यांना न्यायोतर मुद्रांक विक्रेता
Off. Western Express Highway,
Goregaon (East), Mumbai - 400 063.
परवानाधारक मुद्रांक विक्रेता.

SHRI. K. R. MADGE

WHEREAS Piramal Life Sciences limited ("PLSL") has merged its NCE Research Unit into Piramal Healthcare Limited ("PHL") pursuant to a scheme of arrangement approved by the High Court of Mumbai, India vide a Court Order dated November 25, 2011 which is annexed and marked as "Annexure I".

AND WHEREAS the said "ASSIGNOR" holds the entire right, title and interest in the patents and applications for patents as set out in the "Schedule I".

AND WHEREAS the "ASSIGNEE" by virtue of the said order passed by the High Court Mumbai, is entitled to the entire right, title and interest in and to said patents and applications for patents, particulars of which are indicated in "Schedule I" hereto, among other assets and rights vested in it as on December 14, 2011 (hereinafter referred to as the "Effective Date").

AND WHEREAS the "ASSIGNOR" and "ASSIGNEE" wish to enter into the agreement for the assignment of said patents and applications for patents, particulars of which are described in "Schedule I" for a consideration of Rs.1000 (Rupees Ten Thousand only).

55

IN WITNESS WHEREOF the parties hereto have set and subscribed their respective hands hereunto the day and year first herein above written.

SIGNED, SEALED and DELIVERED
On behalf of Assignor the party of the
OTHER PART
PIRAMAL LIFE SCIENCES LIMITED

Somesh Sharma
Dr. Somesh Sharma
Chairman



Witnesses:

1. *Swati Veera*
.....
Senior In-House Patent Attorney

2. *Dr. Ravi Bhat*
.....
Deputy General Manager

SIGNED, SEALED and DELIVERED
On behalf of Assignee, the party of
ONE PART
PIRAMAL HEALTHCARE LIMITED

Rajesh Laddha
.....
Mr. Rajesh Laddha
Chief Financial Officer



Witnesses:

1. *Augustin Fernandes*
.....
General Manager - Finance

2. *Sachin S. Yeling*
.....
GENERAL MANAGER - PURCHASE.

HIGH COURT, BOMBAY

0131743

1

mss

CSP548-49

IN THE HIGH COURT OF JUDICATURE AT BOMBAY

ORDINARY ORIGINAL CIVIL JURISDICTION

COMPANY SCHEME PETITION NO. 548 OF 2011

CONNECTED WITH

COMPANY SUMMONS FOR DIRECTION NO. 438 OF 2011

Piramal Life Sciences Ltd. (PLSL or the
demerged company or transferor company)
And
Piramal Healthcare Ltd. (PHL or the resulting
company or transferee company)
and
Their respective shareholders



Piramal Life Science Ltd. .. Petitioner company

WITH

COMPANY SCHEME PETITION NO. 549 OF 2011

CONNECTED WITH

COMPANY SUMMONS FOR DIRECTION NO. 439 OF 2011

Piramal Life Sciences Ltd. (PLSL or the
demerged company or transferor company)
And
Piramal Healthcare Ltd. (PHL or the resulting
company or transferee company)
and
Their respective shareholders

"Disclaimer Clause : Authenticated copy is not a Certified Copy"

PATENT
REEL: 028527 FRAME: 0882

HIGH COURT, BOMBAY

0131742

2

ms

CSP548-49

Piramal Health Care Ltd.

.. Petitioner company

Mr. Ravi Kadam, Advocate General a/w Ashish Kamat i/b (Chitnis & Co.)
for petitioner.

Mr. H. P. Chaturvedi, G.P. For R.D.

Mr. Bhupendra Champalal Gandhi, Objector present

CORAM: S.C.DHARMADHIKARI, J.

DATED: 25/11/2011

P.C.

The 1st petition is by the transferor company whereas the 2nd petition
is by the transferee.

2. These petitions invoke powers of this court under Section 391 to 394
together with other relevant provisions of the Companies Act, 1956 seeking
confirmation and approval to the Scheme of Arrangement between the
transferor and transferee and their shareholders.

3. In the first petition of the transferor company it has been stated that it
is engaged in the business of research and development of New Chemical
Entities and other Pharmaceutical and herbal products as well as in new

"Disclaimer Clause : Authenticated copy is not a Certified Copy"

PATENT

REEL: 028527 FRAME: 0883

drug delivery systems. The requisite statements of accounts including the provisional statement of account as on 30th June, 2011 are attached. There is also a reference to the aims and objects and the relevant details. It is stated that pursuant to a Scheme of Arrangement which was devised the Board of Directors vide their Resolution dated 6th May, 2011 approved the Scheme of Arrangement. The salient features of the scheme and the rationale behind the same is set out in the petition and subsequently its material provisions are set out.




4. After reference to the material provisions what has been pointed out is that a summons for directions was moved and the court directed the petitioner to convene a meeting of its shareholders. Accordingly the meeting came to be convened and prior thereto all compliances were made with regard to dispatch of notices. The meeting was duly convened on 9th of August, 2011 at Mumbai. Shri Ajay G. Piramal, Chairman of the petitioner acted as Chairman of the meeting of the members and thereafter the proceedings were taken up. The report of the Chairman indicates according to the petitioner, that the overwhelming percentage of members present and voting were 99 representing in value, constituting 95.96% in number and representing 99.99% in value, present and voting in person or

by proxy or by authorized representative voted in favour of the Scheme of Arrangement. 4 members holding 29 equity shares of Rs.10/- fully paid-up, representing in value the sum of Rs.290/- constituting 4.04% in number and representing 0.01% in value, present and voting in person or by proxy or by authorized representative voted against the Scheme. Thus what has been pointed out is that the requisite meetings have been convened. There are other compliances made including filing of the Chairman's report and intimations to the Stock Exchanges. It is stated that the sanctioning of the scheme of arrangement is for the benefit of the company and the shareholders. It would enable the companies to carry on their operations efficiently and smoothly. The base of the companies being pharmaceutical preparations and business also being identical it is stated that the scheme is mutually beneficial to both companies and their respective shareholders. It is based on these compliances that the petition has been placed for hearing and final disposal.

5. The Regional Director has filed an affidavit and has invited attention of this court to the features of the scheme and has stated that the requisite compliances have been made. Further the affidavit filed states that there is no violation of any provisions of the requisite and relevant statutes and

"Disclaimer Clause : Authenticated copy is not a Certified Copy"


enactments. It is stated that save and except clause 6.1 which requires amendment in terms of paragraph 6 of the affidavit and the proposed reorganization of capital structure of Demerged company being given effect to before giving effect to the scheme as set out in paragraph of the affidavit of Regional Director dated 4th November, 2011 the scheme is not prejudicial to the creditors, shareholders and general public.



6. Mr. Kadam, learned Advocate General appearing for the petitioner states that the petitioner in Company Petition No. 548 of 2011 would comply with the requirements that are stipulated in the affidavit of Regional Director and amend clause 6.1 in terms thereof, so also, give effect to the scheme in the manner suggested by the Regional Director. He, therefore, submits that there being no other objection raised by the Regional Director that this court should proceed to grant sanction and approve the scheme.

7. The sole objector, who is appearing and has filed an affidavit is Mr. Bhupendra Champalal Gandhi. In his affidavit he has raised certain issues and particularly that the statements made in the petition and the submissions before this court does not reflect the correct position with regard to the objections of the shareholders, who have spoken at the meeting. He states

that he received the notice and he attended the meeting, spoke there at and also voted. However, the transferee company Piramal Healthcare Limited is a profit making company, which is now going to takeover a loss making venture. That would prejudicially affect the shareholders and their benefits and advantages would go down considerably.




8. My attention is invited to paragraph 8 and 9 of this affidavit and it is contended that the minority shareholders would be affected as the company Piramal Life Science Limited is in losses. Its accumulated losses are enormous. In such circumstances and when the Chairman's report reflects the correct position with regard to the objections and the value of those objectors' shareholding, this court should not approve the scheme.

9. After hearing the learned Advocate General and the counsel appearing for the Regional Director and the sole objector appearing in person, I am of the opinion that going by the stand of the members the scheme has to be approved and sanctioned. It is not for this court to substitute its view with that of the shareholders. The commercial wisdom and the business decisions which have been taken by the shareholders at a duly convened meeting need not be interfered with except for the reasons

"Disclaimer Clause : Authenticated copy is not a Certified Copy"

that are pointed out by the Hon'ble supreme Court in the case of Milheer H. Mafatlal v. Mafatlal Industries Ltd., reported in AIR 1997 SC 506.

10. Similarly, merely because some objectors have appeared before the court to object the scheme on the ground that there objections have not been accepted is also no ground to interfere with the scheme. The majority shareholders have given their approval. The minority who is appearing before this court raised their concerns and were given opportunity to speak at the meeting as well. They have also voted at the meeting.



11. In these circumstances, none of the grounds that have been stated before me on affidavit by the sole objector would enable me to withhold the sanction or approval to the scheme. This is not a case where the exceptions carved out by the Hon'ble Supreme Court would come into play or are attracted.

12. For all these reasons the petitions are allowed and they are made absolute in terms of prayer clauses (a) to (e).

13. The Transferee Company to lodge a copy of this Order and the

"Disclaimer Clause : Authenticated copy is not a Certified Copy"

HIGH COURT, BOMBAY

0131736

8

mss

CSP548-49

Scheme, duly authenticated by the Company Registrar, High Court, Bombay, with the concerned Superintendent of Stamps, for the purpose of adjudication of stamp duty payable, if any, on the same within 60 days from the date of the Order.

14. The Transferee Company to lodge a copy of this Order along with a copy of the Scheme of Arrangement with the concerned Registrar of Companies, electronically, along with E-form 21, in addition to physical copy within 30 days from the date of issuance of the order by the Registry.

15. The petitioners in both the Company Scheme Petitions to pay costs of Rs.10,000/- each to the Regional Director, Western Region, Mumbai. Costs to be paid within four weeks from today.

16. Filing and issuance of the drawn up order is dispensed with.

17. All authorities concerned to act on a copy of this Order along with Scheme duly authenticated by the Company Registrar, High Court, Bombay.

(S. C. DHARMADHIKARI, J.)

TRUE-COPY
[Signature]
12/12/2011
Mrs. K. M. RANE
COMPANY REGISTRAR
HIGH COURT (O.S.)
BOMBAY

TRUE COPY
[Signature]
2.12.11
Section Officer
High Court, Appellate Side
Bombay

"Disclaimer Clause : Authenticated copy is not a Certified Copy"

PATENT

REEL: 028527 FRAME: 0889

IN THE HIGH COURT OF JUDICATURE AT BOMBAY
ORDINARY ORIGINAL CIVIL JURISDICTION
COMPANY SCHEME PETITION NO.548 OF 2011
WITH
COMPANY SUMMONS FOR DIRECTION NO.438 OF 2011
WITH
COMPANY SCHEME PETITION NO.549 OF 2011
WITH
COMPANY SUMMONS FOR DIRECTION NO.439 OF 2011

In the matter of the Companies Act, 1956(1
of 1956)

and

In the matter of Sections 391 to 394 read
with Sections 78 and 100 to 103 of the
Companies Act, 1956;

and

In the matter of Scheme of Arrangement
between:

Piramal Life Sciences Limited (the
demerged/transferor company)

and

Piramal Healthcare Limited (the
Resulting/Transferee company)

and

Their respective shareholders;

Piramal Life Science Limited

.. Petitioner/transferor
company

and

Piramal Healthcare Limited

.. Petitioner/transferee
company

Ms.Renuka Shetty i/b. Chitnis & Co. for petitioners

Mr.C.J.Joy with Soma Singh i/b. H.R.Chaturvedi for Regional Director.

"Disclaimer Clause : Authenticated copy is not a Certified Copy"

PATENT

REEL: 028527 FRAME: 0890

CORAM : S.C.DHARMADHIKARI, J.
8th December 2011.

P.C.:

1] This application for speaking to the minutes has been made so as to seek correction of the order dated 25th November 2011 and also a clarification particularly on the point as to whether the objections of the Regional Director would be complied with and whether the scheme would stand amended as prayed.

2] Both sides state that there are also some corrections in the order and particularly with regard to the prayers that have been granted.

3] After hearing both sides and perusing with their assistance the draft of the proposed corrections to the order I am of the opinion that the request as made deserves to be granted. The order stands corrected and modified as follows:-

1. In para 6 of the order dated 25th November 2011 add the words
"Amendments are allowed. The amendments be carried out within a period of three weeks from today"
2. Similarly, at the end of para 6 the the sentence "undertakings

3
csp548-549.sxw

regarding reorganisation of capital structure of PLSL as per clause 6.1 of the scheme shall be given effect at the first instance, before giving effect to clause 7.1 of the scheme. The undertaking is accepted." be added.

4] Amendments to be carried out within three weeks from today. No other correction and/or modification is required. Rest of the order remains the same. Application for speaking to the minutes is disposed of.

(S.C. Dharmadhikari, J)

TRUE-COPY

Mrs. K. M. Rane
12/12/2011
Mrs. K. M. RANE
COMPANY REGISTRAR
HIGH COURT (O.S.)
BOMBAY

TRUE COPY

[Signature]
3.12.11
Section Officer
High Court, Appellate Side
Bombay

"Disclaimer Clause : Authenticated copy is not a Certified Copy"

SCHEME OF ARRANGEMENT
BETWEEN
PIRAMAL LIFE SCIENCES LIMITED
AND
PIRAMAL HEALTHCARE LIMITED
AND
THEIR RESPECTIVE SHAREHOLDERS

(A) PREAMBLE

This Scheme of Arrangement ('Scheme') is presented under Sections 391 to 394 read with Sections 78, 100 to 103 and other applicable provisions of the Companies Act, 1956 for the demerger of the New Chemical Entity Research Unit (as defined hereinafter) from Piramal Life Sciences Limited ('PLSL') into Piramal Healthcare Limited ('PHL'), on a going concern basis, pursuant to the relevant provisions of the Companies Act, 1956. This Scheme also provides for various other matters consequential or otherwise integrally connected therewith.

(B) PARTS OF THE SCHEME:

This Scheme of Arrangement is divided into the following parts:

- (i) PART I deals with the definitions and share capital;
- (ii) PART II deals with the demerger of New Chemical Entity Research Unit of PLSL into PHL
- (iii) PART III deals with general terms and conditions applicable to this Scheme.

PART I

DEFINITIONS AND SHARE CAPITAL

1. DEFINITIONS

In this Scheme (as defined hereunder), unless inconsistent with the subject or context, the following expressions shall have the following meaning:

- 1.1 "Act" or "the Act" means the Companies Act, 1956, or any statutory modification or re-enactments or amendments thereof for the time being in force;
- 1.2 "Appointed Date" means April 1, 2011 or such other date as may be approved by the High Court;
- 1.3 "Board of Directors" includes any committee or sub – committee of Directors;
- 1.4 "Court" or "High Court" means the High Court of Judicature at Bombay and shall include the National Company Law Tribunal, if and when applicable;
- 1.5 "Effective Date" means the last of the dates on which the certified copy or authenticated copy of the Order of the High Court duly authenticated by the Company

Registrar sanctioning the Scheme is filed by PHL and PLSL with the Registrar of Companies, Mumbai, Maharashtra;

- 1.6 "NCE Research Unit" or "the Demerged Unit" means and includes the New Chemical Entity Research Unit of PLSL proposed to be demerged into PHL and including but not limited to:
- 1.6.1 All assets (whether movable or immovable, real or personal, corporeal or incorporeal, present, future or contingent, tangible or intangible) and liabilities which relate thereto or are necessary therefor and including specifically the following:
- (i) All properties and assets of whatsoever nature and wherever situated, required for / pertaining to NCE Research Unit, including all fixed assets, plant and machinery, equipments, appliances, furniture and fixtures, accessories, vehicles current assets, liquid funds, samples, plant and other extracts, and other properties and assets pertaining to NCE Research Unit;
 - (ii) All the debts (whether secured or unsecured), liabilities (including contingent liabilities), duties and obligations of NCE Research Unit of every kind, nature and description whatsoever and howsoever accruing or arising out of, and all loans and borrowings raised or incurred and utilized for its businesses, activities and operations pertaining to NCE Research Unit;
 - (iii) All rights including lease rights, tenancy rights, permits, quota rights, licenses, titles, intellectual property rights, brands, data, records, photographs and other property collected or acquired, including patents, trade marks and copyrights, whether issued and / or registered or to be issued and / or registered whether applied for or to be applied for, and all tenancies in relation to office powers and facilities of every kind, nature and description whatsoever, all reserves (including balance in Profit and Loss account whether positive or negative and remaining unadjusted or unabsorbed) arising out of or relating to the operations of NCE Research Unit and all the privileges and benefits (including obligations) of all contracts, agreements and arrangements and all other rights, interests, licenses, records, powers and facilities of every kind nature and description, whatsoever pertaining to NCE Research Unit;
 - (iv) All municipal and other statutory and/or regulatory permissions, approvals recognitions, consents, licenses, registrations, subsidies, concessions exemptions, remissions, tax deferrals and all rights and entitlements to use and avail of telephones, telexes, facsimile connections and installations, utilities electricity and other services and all other interests in connection with or pertaining to NCE Research Unit;
 - (v) All records, files, papers, computer programs, right to use the software, manuals data, catalogues, quotations, lists of present and former customers and suppliers, and other records, whether in physical form or electronic form in connection with or relating to NCE Research Unit;
 - (vi) All duties and obligations, which are relating to NCE Research Unit;

For the purpose of this Scheme, it is clarified that liabilities pertaining to NCE Research Unit includes and shall be transferred in the manner as defined in Section 2(19AA) of the Income Tax Act, 1961 as follows:

- The liabilities and debts/obligations at the close of business on the day immediately preceding the Appointed Date which arise out of the activities or operations of the NCE Research Unit;
- All specific loans and borrowings raised, incurred and utilised solely for the activities or operation of NCE Research Unit at the close of business on the day immediately preceding the Appointed Date; and
- Any amounts of general/ multipurpose borrowings at the close of business on the day immediately preceding the Appointed Date, in the same proportion in which the value of the assets pertaining to the NCE Research unit bears to the total value of the assets of PLSL immediately before demerger.

1.6.2 All permanent employees of PLSL working for or employed in NCE Research Unit, as identified and agreed between PLSL and PHL;

1.6.3 Any question that may arise as to whether a specified asset or liability pertains or does not pertain to NCE Research Unit or whether or not it arises out of the activities or operations of NCE Research Unit shall be decided by mutual agreement between the Board of Directors of PLSL and PHL or committee(s) thereof authorized by the respective Board of Directors as on the Effective Date or in such other manner as agreed between PLSL and PHL.



1.7 "PHL" or "the Resulting Company" means Piramal Healthcare Limited, a Company incorporated under the Companies Act, 1956, and having its Registered Office at Piramal Tower, Ganapatrao Kadam Marg, Lower Parel, Mumbai- 400013;

1.8 "PLSL" or "Demerged Company" means Piramal Life Sciences Limited, a Company incorporated under the Companies Act, 1956, and having its Registered Office at Piramal Tower, Ganapatrao Kadam Marg, Lower Parel, Mumbai- 400013;

1.9 "Record Date" means the date to be fixed jointly by the Board of Directors of PHL and PLSL for the purpose of determining the shareholder(s) of PLSL to whom the shares of PHL will be allotted pursuant to this Scheme becoming effective;

1.10 "Remaining Business" means all the businesses and undertakings, divisions and their respective assets and liabilities (including accumulated and unabsorbed tax losses and accumulated and unabsorbed depreciation, if any, as per provisions of Section 72A of the Income tax Act, 1961) of PLSL other than NCE Research Unit;

- 1.11 "Scheme" or "the Scheme" or "this Scheme" means this Scheme of Arrangement in its present form as submitted to the High Court or this Scheme with such modification(s), if any made, as per Clause 16 of the Scheme

All terms and words not defined in this Scheme shall, unless repugnant or contrary to the context or meaning thereof, have the same meaning ascribed to them under the Act, the Income Tax Act, 1961, the Securities Contract Regulation Act, 1956, the Depositories Act, 1996 and other applicable laws, rules, regulations, bye-laws, as the case may be or any statutory modification or re-enactment thereof from time to time.

2. DATE OF TAKING EFFECT AND OPERATIVE DATE

- 2.1 The Scheme set out herein in its present form or with any modification(s) approved or imposed or directed by the High Court, shall be effective from the Appointed Date but shall be operative from the Effective Date.
- 2.2 Any reference in this Scheme to "upon the Scheme becoming effective" or "effectiveness of the Scheme" or "upon the coming into effect of the Scheme" shall mean the Effective Date.

3. SHARE CAPITAL

- 3.1 The authorized, issued, subscribed and paid-up share capital of PHL as on March 3, 2011 is as under:

Share Capital	Amount in Rs
<u>Authorized Share Capital</u>	
25,00,00,000 Equity shares of Rs. 2/- each	50,00,00,000
30,00,000 Preference Shares of Rs. 100/- each	30,00,00,000
2,40,00,000 Preference Shares of Rs. 10/- each	24,00,00,000
10,50,00,000 Unclassified Shares of Rs. 2/- each	21,00,00,000
Total	125,00,00,000
<u>Issued and Subscribed</u>	
16,79,16,044 Equity Shares of Rs. 2/- each	33,58,32,088
Total	33,58,32,088

Subsequent to the above date, while there is no change in the authorized share capital, the issued, subscribed and paid up share capital of PHL has been changed and the present authorised, issued, subscribed and paid up share capital of PHL is as under:

Share Capital	Amount in Rs
	PATENT

<u>Authorized Share Capital</u>	
25,00,00,000 Equity shares of Rs. 2/- each	50,00,00,000
30,00,000 Preference Shares of Rs. 100/- each	30,00,00,000
2,40,00,000 Preference Shares of Rs. 10/- each	24,00,00,000
10,50,00,000 Unclassified Shares of Rs. 2/- each	21,00,00,000
Total	125,00,00,000
Share Capital	Amount in Rs
<u>Issued, Subscribed and Paid-up</u>	
16,72,10,515 Equity Shares of Rs. 2/- each	33,44,21,030
Total	33,44,21,030

3.2 The authorized, issued, subscribed and paid-up share capital of PLSL as on March 31, 2011 is as under:

Share Capital	Amount in Rs.
<u>Authorized Share Capital</u>	
3,00,00,000 Equity Shares of Rs. 10/- each	30,00,00,000
Total	30,00,00,000
<u>Issued and Subscribed</u>	
2,54,51,314 Equity Shares of Rs. 10/- each	25,45,13,140
Total	25,45,13,140

Subsequent to the above date, while there is no change in the authorized share capital, the issued, subscribed and paid up share capital of PLSL has been changed and the present authorised, issued, subscribed and paid up share capital of PLSL as under:

Share Capital	Amount in Rs.
<u>Authorized Share Capital</u>	
3,00,00,000 Equity Shares of Rs. 10/- each	30,00,00,000
Total	30,00,00,000
<u>Issued and Subscribed</u>	
2,59,60,340 Equity Shares of Rs. 10/- each	25,96,03,400
Total	25,96,03,400

PART II

DEMERGER, TRANSFER AND VESTING OF NCE RESEARCH UNIT

PATENT

REEL: 028527 FRAME: 0897

4. TRANSFER AND VESTING OF NCE RESEARCH UNIT

Upon the coming into effect of this Scheme and with effect from the Appointed Date the whole of the undertaking, assets, properties and liabilities of the NCE Research Unit as defined in Clause 1.6 shall stand transferred to and vested in and / or be deemed to be transferred to and vested as a going concern in PHL in the following manner:

- 4.1 With effect from the Appointed Date the NCE Research Unit shall, under the provisions of Sections 391 to 394 and all other applicable provisions, if any, of the Act, and without any further act or deed, be transferred to and vested in and/ or be deemed to be transferred to and vested in PHL, so as to vest in PHL, all the rights, title and interest of PLSL therein, existing as at the opening of the business day on the Appointed Date.
- 4.2 All the movable assets pertaining to NCE Research Unit which are capable of being physically transferred including cash on hand shall be physically handed over by delivery to PHL to the end and intent that the property therein passes to PHL. Such delivery and transfer shall be made on a date to be mutually agreed upon between the respective Boards of Directors or Committees thereof of PLSL and PHL.
- 4.3 In respect of any assets pertaining to NCE Research Unit, including actionable claims, sundry debtors, outstanding loans, advances recoverable in cash or kind or for value to be received and deposits with the Government, semi-Government, local and other authorities and bodies and customers, PHL may, and PLSL shall, on being so requested by PHL, issue notices in such form as PHL specifies stating that pursuant to the High Court having sanctioned this Scheme under Sections 391 and 394 of the Act, the relevant debt, loan, advance, deposit or other asset, be paid or made good to, or be held on account of, PHL as the person entitled thereto, to the end and intent that the right of PLSL to receive, recover or realize the same, stands transferred to PHL and appropriate entries should be passed in their respective books to record the aforesaid changes.
- 4.4 With effect from the Appointed Date and upon the Scheme becoming effective, any statutory licenses, registrations, permissions or approvals or consents relating to and/or held for carrying on operations of the NCE Research Unit shall stand vested in or transferred to PHL without any further act or deed, and shall be appropriately mutated by the statutory authorities concerned therewith in favour of PHL. The benefit of all statutory and regulatory permissions, registration or other licenses, and consents shall vest in and become available to PHL pursuant to the Scheme. In so far as the various incentives, subsidies, special status and other benefits or privileges granted by any Government body, local authority or by any other person, or enjoyed and availed in relation to NCE Research Unit, are concerned, the same shall vest with and be available to PHL on the same terms and conditions.



4.5 With effect from the Appointed Date, all debts, liabilities, contingent liabilities, duties and obligations of every kind, nature and description relating to the NCE Research Unit shall also, under the provisions of Sections 391 to 394 and all other applicable provisions, if any, of the Act, and without any further act or deed, be transferred to or be deemed to be transferred to PHL, so as to become from the Appointed Date the debts, liabilities, contingent liabilities, duties and obligations of PHL and it shall not be necessary to obtain the consent of any third party or other person who is a party to any contract or arrangement by virtue of which such debts, liabilities, contingent liabilities, duties and obligations have arisen in order to give effect to the provisions of this sub-clause.

4.6 All the existing securities, mortgages, charges, encumbrances or liens, if any, over the assets comprised in or relating to the liabilities of the NCE Research Unit transferred to PHL by virtue of this Scheme, shall, after the Effective Date, continue to relate and attach to such assets or any part thereof to which they are related or attached prior to the Effective Date.

4.7 It is clarified that if any assets (estate, claims, rights, title, interest in or authorities relating to such assets) or any contract, deeds, bonds, agreements, schemes, arrangements or other instruments of whatsoever nature in relation to PLSL, which PLSL owns or to which PLSL is a party to, cannot be transferred to PHL for any reason whatsoever, PLSL shall hold such assets or contracts, deeds, bonds, agreements, schemes, arrangements or other instruments of whatsoever nature, in trust for the benefit of PHL, insofar as it is permissible so to do, till such time as the transfer is effected.

4.8 Any existing encumbrances over the assets and properties of PHL or any part thereof which relate to the liabilities and obligations of PHL prior to the Effective Date shall continue to relate only to such assets and properties and shall not extend or attach to any of the assets and properties of the NCE Research Unit transferred to and vested in PHL by virtue of this Scheme.

4.9 Amongst other things, this Scheme has been drawn up to comply with the conditions relating to "Demerger" as specified under Section 2(19AA) of the Income-tax Act, 1961. If any terms or provisions of the Scheme are found or interpreted to be inconsistent with the provisions of the said Section at a later date including resulting from an amendment of law or for any other reason whatsoever, the provisions of the said Section of the Income-tax Act, 1961 shall prevail and the Scheme shall stand modified to the extent determined necessary to comply with Section 2(19AA) of the Income-tax Act, 1961. Such modification will however not affect the other parts of the Scheme.

5. ISSUE OF SHARES BY PHL

- 5.1 Upon coming into effect of the Scheme and in consideration for the transfer and vesting of the NCE Research Unit in PHL, PHL shall, without any further application or deed, issue and allot shares, credited as fully paid up, to the extent indicated below, to the members of PLSL whose name appears in the Register of Members of PLSL as on the Record Date or to their respective heirs, executors, administrators or other legal representatives or the successors-in-title, as the case may be, in the following manner:

"1 (One) fully paid equity share of Rs. 2 (Rupees Two) each of PHL shall be issued and allotted for every 4 (Four) equity shares of Rs. 10 (Rupees Ten) each held in PLSL."

It is expressly clarified that no shares will be issued against shares held by PHL in PLSL.

- 5.2 The Board of Directors of PHL shall consolidate all fractional entitlement(s), if any, arising and allot Shares in lieu thereof to a director or an officer of PHL or such other person as the Board of Directors of PHL shall appoint in this behalf who shall hold the shares in trust on behalf of the members entitled to fractional entitlements with the express understanding that such director(s) or officer(s) or person(s) shall sell the same at such time or times and at such price or prices and to such person or persons, as it/ he/ they may deem fit, and pay to PHL, the net sale proceeds thereof, whereupon PHL shall distribute such net sale proceeds, subject to taxes, if any, to the members in proportion to their respective fractional entitlements.

- 5.3 The Equity Shares (to be issued to the members of PLSL as above) shall be subject to the Memorandum and Articles of Association of PHL and shall rank *pari passu* with the existing equity shares of PHL in all respects including dividends.

- 5.4 The Equity Shares (to be issued to the members of PLSL as above) shall be issued in dematerialized form to those shareholders who hold shares of PLSL in dematerialized form, in to the account in which PLSL shares are held or such other account as is intimated by the shareholders to PLSL and / or its Registrar before the Record Date. All those shareholders who hold shares of PLSL in physical form shall also have the option to receive the Equity Shares, as the case may be, in dematerialized form provided the details of their account with the Depository Participant are intimated in writing to PLSL and / or its Registrar before the Record Date. Otherwise, they would be issued Equity Shares in physical form. The Equity shares of PHL allotted pursuant to the Scheme shall remain frozen in the depositories system till listing and trading permission is given by the designated Stock Exchange.

- 5.5 PHL shall, if and to the extent required, apply for and obtain any approvals from concerned Regulatory authorities for the issue and allotment of equity shares to the members of PLSL pursuant to clause 5.1 of the Scheme.

- 5.6 The equity shares to be issued to the members of PLSL pursuant to clause 5.1 of this Scheme will be listed and/or admitted to trading on all the stock exchanges on which

PATENT

REEL: 028527 FRAME: 0900

shares of PLSL are listed on the Effective Date. PHL shall enter into such arrangements and give such confirmations and/or undertakings as may be necessary in accordance with the applicable laws or regulations for complying with the formalities of the said stock exchanges.

5.7 The equity shares to be issued by PHL to the members of PLSL pursuant to clause 5.1 of this Scheme, in respect of any shares in PLSL which are held in abeyance under the provisions of Section 206A of the Act or otherwise, pending allotment or settlement of dispute, by order of court or otherwise, be held in abeyance by PHL.

5.8 In the event of there being any pending share transfers, whether lodged or outstanding, of any shareholder of PLSL, the Board of Directors of PLSL shall be empowered in appropriate cases, prior to or even subsequent to the Record Date, to effectuate such a transfer in PLSL as if such changes in registered holder were operative as on the Record Date, in order to remove any difficulties arising to the transferor or transferee of the share in PLSL in respect of shares issued by PHL upon the effectiveness of this Scheme. The Board of Directors of PHL shall also be empowered to remove such difficulties as may arise in the course of implementation of this Scheme and registration of new members in PHL on account of difficulties faced in the transition period.

5.9 Approval of this Scheme by the shareholders of PHL shall be deemed to be their consent and due compliance of the provisions of Section 81(1A) and the other relevant and applicable provisions of the Act for the issue and allotment of equity shares by PHL to the shareholders of PLSL, as provided in this Scheme.



6. RE-ORGANIZATION OF CAPITAL STRUCTURE OF PLSL

6.1 Upon the Scheme becoming effective, the balance in the Securities Premium account of PLSL as on the Appointed Date shall be utilized to adjust the debit balance in Profit and Loss account pertaining to NCE Research Unit to the extent feasible.

6.2 The utilisation of Securities Premium account, as above, shall be effected with from the Appointed Date and as an integral part of the Scheme itself in accordance with the provisions of Section 78 and Sections 100 to 103 of the Act without following the process(es) under sections 100 to 103 of the Act separately as the same does not involve either diminution of liability in respect of unpaid share capital or payment to any shareholder of any paid-up share capital and the order of the High Court sanctioning the Scheme shall be deemed to be an order under Section 102 of the Act confirming the reduction and no separate sanction under sections 100-102 of the Act will be necessary.

7. ACCOUNTING TREATMENT IN THE BOOKS OF PHL AND PLSL

7.1 IN THE BOOKS OF PLSL

Upon the Scheme becoming effective:

7.1.1 PLSL shall reduce the book value of assets, liabilities and reserves (including debit balance in Profit and Loss account which cannot be adjusted as per Clause 6 above) pertaining to the NCE Research Unit from its books of account.

7.1.2 The difference arising in the balance sheet of PLSL after giving effect to clause 7.1.1 above shall be recorded as Capital Reserve or Goodwill, as the case may be.

7.2 IN THE BOOKS OF PHL

Upon the Scheme becoming effective:

7.2.1 PHL shall record the assets and liabilities pertaining to the NCE Research Unit, at the respective book values as on the opening of business hours on the Appointed Date.

7.2.2 PHL shall credit to its share capital account, the aggregate face value of the Equity Shares issued by it pursuant to Clause 5.1 of this Scheme.

7.2.3 Loans and advances and other dues outstanding between PHL and PLSL pertaining to NCE Research Unit will stand cancelled and there shall be no further obligation / outstanding in that behalf.

7.2.4 The reserves (including debit balance in Profit and Loss account which cannot be adjusted as per Clause 6 above) pertaining to NCE Research Unit shall be recorded in PHL in the same manner as appearing in the books of PLSL and as an addition or adjustment to the similar reserve / balance appearing in the books of PHL.

7.2.5 The difference arising in the balance sheet of PHL after giving effect to Clause 7.2.1 to 7.2.4 shall be recorded as Capital Reserve or Goodwill as the case may be.

8. TRANSACTIONS BETWEEN APPOINTED DATE AND EFFECTIVE DATE

With effect from the Appointed Date and up to the Effective Date:

8.1 PLSL shall carry on and be deemed to have carried on its business and activities relating to NCE Research Unit and shall be deemed to have held and stood possessed of and shall hold and stand possessed of its entire businesses and undertakings relating to NCE Research Unit for and on account of and in trust for PHL.

8.2 All the profits or income accruing or arising to PLSL relating to NCE Research Unit or expenditure or losses arising or incurred by PLSL relating to NCE Research Unit shall for all purposes be treated and deemed to be and accrue as the profits or income or expenditure or losses (as the case may be) of PHL.

- 8.3 PHL shall be entitled, pending the sanction of the Scheme, to apply to the Central Government and all other agencies, departments and authorities concerned as are necessary under any law for such consents, approvals and sanctions which PHL may require to carry on the business of NCE Research Unit.
- 8.4 PLSL shall not utilize its income of NCE Research Unit for any purpose (other than in the ordinary course of its business) in respect of the period falling on and after the Appointed Date, without the prior written consent of the Board of Directors of PHL.
- 8.5 PLSL shall not without the prior written consent of the Board of Directors of PHL, sell, transfer or otherwise alienate, charge, mortgage or encumber or otherwise deal with or dispose of its undertaking relating to NCE Research Unit or any part thereof or any material assets, except in the ordinary course of its business or pursuant to any pre-existing obligation.
- 8.6 PLSL shall not, without the prior written consent of the Board of Directors of PHL, vary the terms and conditions of service of the employees working for the NCE Research Unit except in the ordinary course of its business or consistent with past practice or pursuant to any pre-existing obligation.



With effect from the date of filing of this Scheme with the High Court and up to and including the Effective Date, PLSL and PHL shall not issue any further shares, (either on a rights basis, public issue, bonus shares, convertible debentures or otherwise), decrease, reduction, reclassification, subdivision or consolidation, re-organisation, or in any other manner which may, in any way, affect the share exchange ratio under the Scheme, except by mutual consent of the respective Boards of Directors of the PLSL and PHL or unless such change is pursuant to any pre-existing obligation or unless any such change in the capital structure has commenced prior to the filing of this Scheme or unless the same is in accordance with the provisions of this Scheme.

- 8.8 In the event that PHL restructures its equity share capital by way of share split / consolidation / issue of bonus shares during the pendency of the Scheme, the share exchange ratio (as provided in the Clause 5.1 shall be adjusted accordingly to take into account the effect of such corporate actions.
- 8.9 For the avoidance of doubt, it is hereby clarified that nothing in this Scheme shall prevent the PHL from declaring and paying dividends, whether interim or final, to its equity shareholders as on the respective record date for the purpose of dividend and the shareholders of the PLSL shall not be entitled to dividends, if any, declared by the PHL prior to the Effective Date.

PART III
GENERAL TERMS AND CONDITIONS

9. STAFF , WORKMEN & EMPLOYEES

9.1 On the Scheme becoming effective, all permanent staff, workmen and employees of PLSL working for the NCE Research Unit, who are in service as on the Effective Date shall be deemed to have become staff, workmen and employees of PHL, with effect from the Appointed Date, without any break in their service and on the basis of continuity of service, and the terms and conditions of their employment with PHL shall not be less favorable than those applicable to them with reference to their employment with PLSL on the Effective Date. PHL agrees that the services of all such employees with PLSL up to the Effective Date shall be taken into account for purposes of all retirement benefits to which they may be eligible in PLSL on the Effective Date. Any question that may arise as to whether any staff, workman or employee belongs to or does not belong to NCE Research Unit, shall be decided mutually by Board of Directors of PLSL and PHL or committee(s) thereof.

9.2 It is expressly provided that, on the Scheme becoming effective, the Provident Fund, Gratuity Fund, Superannuation Fund or such other Special Fund, if any, or Trusts, including PLSL Employees Stock Option Plan Trust (hereinafter collectively referred 'Funds') created for the benefit of the staff, workmen and employees of PLSL shall to the extent they relate to the staff, workmen and employees working for the Research Unit, become Funds of PHL, or shall be transferred to PHL for all purposes whatsoever in relation to the administration or operation of such Funds or in relation to the obligation to make contributions to the said Funds in accordance with the provisions thereof as per the terms provided in the respective Trust Deeds, if any, to the end and intent that all rights, duties, powers and obligations of PLSL in relation to such Funds shall become those of PHL. It is clarified that the services of the staff, workmen and employees working for the NCE Research Unit will be treated as having been continuous for the purpose of the said Funds.

9.3 In the event that PHL does not have its own Funds in respect of any of the above, PLSL, may subject to necessary approvals and permissions, continue to contribute to the relevant Funds of PLSL, until such time as PHL creates its own Funds, at which time the Funds and the investment and contributions, pertaining to staff, workmen and employees working for NCE Research Unit shall be transferred to the funds created by PHL.

10. EMPLOYEE STOCK OPTION PLAN


10.1 In respect of the outstanding employee stock option under PLSL Employees Stock Option Plan ("PLSL Option Scheme"), it is hereby clarified that the options which have

been granted but have not been vested in the hands of the employees of the NCE Research Unit as of the Effective Date would lapse.

10.2 Further, the options under the PLSL Option Scheme which, as of the Effective Date, have been vested in employees of the NCE Research Unit but have not been exercised, would lapse if not exercised before the Record Date.

10.3 PHL shall offer its stock option on terms and conditions not less favourable to the employees than those of the PLSL Option Scheme which will be offered to such employees of the NCE Research Unit whose options under the PLSL Option Scheme have lapsed pursuant to Clause 10.1 and 10.2 above, after making suitable adjustments to the number of shares to be issued and/or the exercise price.

11. CONTRACTS, DEEDS, ETC.



Subject to the other provisions of this Scheme, all contracts, deeds, bonds, agreements, insurance policies and other instruments, if any, of whatsoever nature relating to NCE Research Unit and to which PLSL is a party and subsisting or having effect on the Effective Date, shall be in full force and effect against or in favour of PHL, and may be enforced by or against PHL as fully and effectually as if, instead of PLSL, PHL had been a party thereto. PHL shall enter into and/ or issue and/ or execute deeds, writings or confirmations or enter into any tripartite arrangements, conformations or novations, to which PLSL will, if necessary, also be a party in order to give formal effect to the provisions of this Scheme, if so required or becomes necessary. PHL shall be deemed to be authorized to execute any such deeds, writings or confirmations on behalf of PLSL and to implement or carry out all formalities required on the part of PLSL to give effect to the provisions of this Scheme.

12. SAVING OF CONCLUDED TRANSACTIONS

The transfer and vesting of NCE Research Unit as above and the continuance of proceedings by or against PLSL in relation to NCE Research Unit shall not affect any transaction or proceedings already concluded on or after the Appointed Date till the Effective Date, to the end and intent that PHL accepts and adopts all acts, deeds and things done and executed by PLSL in respect thereto as done and executed on behalf of themselves.

13. REMAINING BUSINESS

The Remaining Business and all assets, liabilities and obligations pertaining thereto shall continue to belong to and remain in and managed by PLSL.

14. APPLICATION TO HIGH COURT

PHL and PLSL shall make applications/ petitions as applicable under Sections 391 to 394 read with Sections 78, 100 to 103 and other applicable provisions of the Act to the High Court for holding/dispensing with the meetings of the shareholders and/or creditors of both the Companies and for sanction of this Scheme under the provisions of law.

15. CONTINUATION OF LEGAL PROCEEDINGS AND INDEMNIFICATION

15.1 Upon the coming into effect of the Scheme, all legal proceedings of whatsoever nature by or against PLSL pending and/ or arising on or after the Appointed Date and relating to NCE Research Unit, shall not abate or be discontinued or be in any way prejudicially affected by reason of the Scheme or by anything contained in this Scheme but shall be continued and enforced by or against PHL, as the case may be, in the same manner and to the same extent as it would have been continued and enforced by or against PLSL.

15.2 If the proceedings are taken against PLSL in respect of the matters referred to in sub Clause 15.1, it shall defend the same in accordance with the advice of PHL and at the cost of PHL, and the latter shall reimburse any or all payments made by PLSL and indemnify, hold harmless PLSL against all liabilities and obligations incurred by PLSL in respect thereof.

15.3 PHL undertakes to have all legal or other proceedings initiated by or against PLSL referred to in sub-Clause 15.1 transferred into its own name (PHL) and to have the same continued, prosecuted and enforced by or against PHL to the exclusion of PLSL.

In the event of any difference or difficulty as to whether any specific legal or other proceeding relates to NCE Research Unit or not, a certificate jointly issued by the Board of Directors of PLSL and PHL as to whether such proceeding relates to NCE Research Unit or not, shall be conclusive evidence of the matter.

16. MODIFICATION OR AMENDMENTS TO THE SCHEME

PHL and PLSL by their respective Boards of Directors may assent to/make and/or consent to any modifications/amendments to the Scheme or to any conditions or limitations that the Court and/or any other Authority under law may deem fit to direct or impose, or which may otherwise be considered necessary, desirable or appropriate as a result of subsequent events or otherwise by them (i.e. the Board). PHL and PLSL by their respective Boards are authorised to take all such steps as may be necessary, desirable or proper to resolve any doubts, difficulties or questions whatsoever for carrying the Scheme, whether by reason of any directive or Orders of any other authorities or otherwise howsoever, arising out of or under or by virtue of the Scheme and/or any matter concerned or connected therewith.

17. CONDITIONALITY OF THE SCHEME

This Scheme is and shall be conditional upon and subject to:

- 17.1 The requisite consent, approval or permission of the Central Government or any other statutory or regulatory authority, which by law may be necessary for the implementation of this Scheme.
- 17.2 The Scheme being approved by the requisite majority in number and value of such classes of persons including the respective members and/or creditors of PHL and PLSL as may be directed by the High Court.
- 17.3 The Scheme being sanctioned by the Bombay High Court or any other authority under Sections 391 to 394 read with Section 78, 100 to 103 and other applicable provisions of the Act.
- 17.4 Certified or authenticated copy of the Order of the High Court sanctioning the Scheme being filed with the Registrar of Companies, Maharashtra at Mumbai by PHL and PLSL as may be applicable.

18. EFFECT OF NON-RECEIPT OF APPROVALS

In the event of any of the said sanctions and approvals referred to in the preceding clause not being obtained and/ or the Scheme not being sanctioned by the High Court or such other competent authority and / or the Order not being passed as aforesaid before March 31, 2012 or within such further period or periods as may be agreed upon between PHL and PLSL by their respective Board of Directors (and which the Board of Directors of the Companies are hereby empowered and authorised to agree to and extend the Scheme from time to time without any limitation), this Scheme shall stand revoked, cancelled and be of no effect, save and except in respect of any act or deed done prior thereto as is contemplated hereunder or as to any rights and/ or liabilities which might have arisen or accrued pursuant thereto and which shall be governed and be preserved or worked out as is specifically provided in the Scheme or as may otherwise arise in law.

19. COSTS, CHARGES & EXPENSES

All costs, charges, taxes including duties, levies and all other expenses, if any (save as expressly otherwise agreed) of PHL and PLSL arising out of or incurred in carrying out and implementing this Scheme and matters incidental thereto shall be borne by PHL.

TRUE-COPY
[Signature]
 12.12.2011
Mrs. K. M. RANE
 COMPANY REGISTRAR
 HIGH COURT (O.S.)
 BOMBAY

TRUE COPY
[Signature]
 (Sole Proprietor)
CHITNIS & CO.
 ADVOCATES

IN THE HIGH COURT OF JUDICATURE AT
BOMBAY
ORDINARY ORIGINAL CIVIL JURISDICTION
CO. SCHEME PETITION NO. 549 OF 2011

CONNECTED WITH

CO. SUMMONS FOR DIRECTION NO. 439 OF
2011

In the matter of the Companies Act, 1956;

And

In the matter of Sections 391 to 394 read
with Sections 78 and 100 to 103 of the
Companies Act, 1956;

AND

In the matter of Scheme of Arrangement
between

Piramal Life Sciences Limited ('PLSL' or
'the Demerged Company' or 'Transferor
Company')


and

Piramal Healthcare Limited ('PHL' or 'the
Resulting Company' or 'Transferee
Company')

and

Their respective Shareholders

Piramal Healthcare Limited. ... Petitioner /
Transferee Company



Authenticated copy of the Minutes of Order dated
25th November, 2011 and 8th December, 2011
alongwith the Scheme of Arrangement annexed to the
Petition.

Applied on..... 28/11/2011
Engrossed on..... 09/12/2011
Section Writer.....
Folios.....
Examined by.....
Compared with.....
Ready on..... 13/12/2011
Delivered on..... 13/12/2011

M/s Chitnis & Co.
Advocates for the Petitioner
1st Floor, 3/B Ismail Building,
381, Dr. D. N. Road,
Near American Dryfruit,
Fort, Mumbai - 400 023

SCHEDULE I

Title						
INHIBITORS OF CYCLIN-DEPENDENT KINASES AND THEIR USE						
Applicant						
PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date	
A. US Patent Application						
	10/611,539	July 1, 2003	Granted	US 7271193	September 18, 2007	
CIP Application of US Application: 10/611,539	11/530,272	September 8, 2006	Granted	US 7884127	February 8, 2011	
Divisional application of US application: 10/611,539	11/779,577	July 18, 2007	Granted	US 7915301	March 29, 2011	
Continuation Application of US 11/779,577	13/026,503	February 14, 2011	Allowed for grant			
B. National Phase Filing In Different Countries Through PCT Route						
Australia	2003272070	July 7, 2003	Granted	2003272070	May 26, 2009	
Brazil	PI 0312633-1	July 7, 2003	Pending			
Canada	2492130	July 7, 2003	Granted	2492130	September 6, 2011	
China	03816324.1	July 7, 2003	Allowed for grant			
Europe	03753911.1	July 7, 2003	Granted	EP 1556375 B	June 25, 2008	
India	0015/MUMNP/2005	July 7, 2003	Granted	251454	March 21, 2012	
Israel	166153	July 7, 2003	Granted	166153	February 19, 2010	

PATENT

REEL: 028527 FRAME: 0909

SCHEDULE I

Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
Japan	519151/2004	July 7, 2003	Granted	4860148	November 11, 2011
Mexico	PA/a/2005/000388	July 7, 2003	Granted	260700	September 22, 2008
New Zealand	537518	July 7, 2003	Granted	537518	February 29, 2008
Russia	2005102939	July 7, 2003	Granted	2334746	September 27, 2008
South Africa	2005/00138	July 7, 2003	Granted	2005/00138	February 22, 2006
South Korea	10-2005-7000401	July 7, 2003	Granted	10-0991920	October 28, 2010
C. NON-PCT Patent Applications					
Argentina	P030102432	July 3, 2003	Pending		
Taiwan	092117185	June 24, 2003	Granted	92117185	October 1, 2010

SCHEDULE I

Title		NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS				
Applicant		PIRAMAL LIFE SCIENCES LIMITED				
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
A. National Phase Filing In Different Countries Through PCT Route						
	Australia	2006344987	June 21, 2006	Pending	2006344987	January 22, 2009
	Brazil	PI0621777-0	June 21, 2006	Pending		
	Canada	2655789	June 21, 2006	Pending	2655789	December 27, 2007
	China	200680055077.2	June 21, 2006	Pending		
	Europe	06765803.9	June 21, 2006	Pending	2046738	April 15, 2009
	Hong Kong	09105576.2	June 21, 2006	Pending	1126761	September 11, 2009
	India	0138/MUMNP/2009	June 21, 2006	Pending	0138/MUMNP/2009	May 15, 2009
	Israel	195850	June 21, 2006	Pending		
	Japan	2009515971	June 21, 2006	Pending	2009541294	November 26, 2009
	Mexico	MX/a/2008/016398	June 21, 2006	Pending		
	New Zealand	574266	June 21, 2006	Granted	574266	February 7, 2012
	Russia	2008152246	June 21, 2006	Granted	2418786	May 20, 2011
	South Africa	2008/10756	June 21, 2006	Pending		
	South Korea	10-2009-7001021	June 21, 2006	Pending	20090023705	March 5, 2009
	USA	12/305,815	June 21, 2006	Pending	US 20100179210	July 15,2010
B. NON-PCT Patent Applications						
	Argentina	P070102738	June 21, 2007	Pending	61567	September 3, 2008
	Taiwan	096122190	June 20, 2007	Pending		

SCHEDULE I

Title		AN ENANTIOSELECTIVE SYNTHESIS OF PYRROLIDINES SUBSTITUTED WITH FLAVONES AND INTERMEDIATES THEREOF				
Applicant		PIRAMAL LIFE SCIENCES LIMITED				
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
A. National Phase Filing in Different Countries Through PCT Route						
	Australia	2006346193	July 7, 2006	Pending	2006346193	January 29, 2009
	Brazil	PI0621851-2	July 7, 2006	Pending		
	Canada	2658215	July 7, 2006	Pending	2658215	January 17, 2008
	China	200680055257	July 7, 2006	Pending	101484445	July 15, 2009
	Europe	06766035.7	July 7, 2006	Granted	EP 2041121 B	July 27, 2011
	Hong Kong	09105577.1	July 7, 2006	Granted	HK1126762B	February 3, 2012
	India	0286/MUMNP/2009	July 7, 2006	Pending	0286/MUMNP/2009	May 8, 2009
	Israel	196298	July 7, 2006	Pending	196298	September 22, 2009
	Japan	2009-518985	July 7, 2006	Allowed for grant		
	Mexico	MX/a/2009/000109	July 7, 2006	Granted	290492	September 27, 2011
	New Zealand	573841	July 7, 2006	Granted	573841	March 5, 2012
	Russia	2009103916	July 7, 2006	Granted	2404965	November 27, 2010
	South Africa	2009/00900	July 7, 2006	Granted	2009/00900	July 28, 2010
	South Korea	10-2009-7002349	July 7, 2006	Pending	20090033465	April 3, 2009
	USA	12/307,645	July 7, 2006	Granted	US 7951961	May 31, 2011
B. NON-PCT Patent Applications						
	Argentina	P070103023	July 6, 2007	Pending		
	Taiwan	096122651	June 22, 2007	Pending	200815413	April 1, 2008

SCHEDULE I

Title						
A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER						
Applicant						
PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
A. National Phase Filing In Different Countries Through PCT Route						
	Australia	2007353129	May 15, 2007	Pending	2007353129	November 20, 2008
	Brazil	PI0721626-2	May 15, 2007	Pending		
	Canada	2687204	May 15, 2007	Pending	2687204	November 20, 2008
	China	200780052995.4	May 15, 2007	Pending	101677567	March 24, 2010
	Europe	07735911.5	May 15, 2007	Granted	EP 2154971 B	December 28, 2011
	India	2304/MUMNP/2009	May 15, 2007	Pending		
	Israel	202014	May 15, 2007	Pending	202014	June 16, 2010
	Japan	2010-507996	May 15, 2007	Pending	2010526862	August 5, 2010
	Mexico	MX/Ja/2009/012155	May 15, 2007	Allowed for grant		
	New Zealand	581183	May 15, 2007	Allowed for grant		
	Russia	2009146008	May 15, 2007	Granted	2438664	January 10, 2012
	South Africa	2009/08896	May 15, 2007	Allowed for grant		
	South Korea	10-2009-7025837	May 15, 2007	Pending	1020100017763	February 16, 2010
	USA	12/600,019	May 15, 2007	Pending	US 20100305057	December 2, 2010
B. NON-PCT Patent Applications						
	Argentina	P080102040	May 14, 2008	Pending	66564	August 26, 2009
	Taiwan	097116343	May 2, 2008	Pending	200913991	April 1, 2009

SCHEDULE I

Title	NOVEL SYNERGISTIC COMBINATION OF GEMCITABINE WITH P276-00 OR P1446A IN TREATMENT OF CANCER					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
A. Indian Patent Application						
	India	699/MUM/2008	March 31, 2008	Granted	250374	December 30, 2011
	India	3354/MUM/2011	November 30, 2011	Pending		
B. US Patent Application						
Divisional of CIP appln no. 12/653,012	USA	13/157,075	June 9, 2011	Pending	US20110312528	December 22, 2011

SCHEDULE I

Title	INTERFERON EPSILON (IFNE1) AS A MARKER FOR TARGETED CANCER THERAPY						
Applicant	PIRAMAL LIFE SCIENCES LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date	
National Phase Filing In Different Countries Through PCT Route							
	Australia	2008357875	June 10, 2008	Pending	2008357875	December 17, 2009	
	Europe	08763271.7	June 10, 2008	Pending	2307561	April 13, 2011	
	India	0022/MUMNP/2011	June 10, 2008	Pending			
	US CIP	12/964,417	June 10, 2008	Pending	US 20110151469	June 23, 2011	

SCHEDULE I

Title		PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER				
Applicant		PIRAMAL LIFE SCIENCES LIMITED				
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
A. National Phase Filing In Different Countries Through PCT Route						
	Australia	2010244101	May 3, 2010	Pending	2010244101	January 12, 2012
	Brazil	20110113201	May 3, 2010	Pending		
	Canada	2761182	May 3, 2010	Pending	2761182	January 6, 2012
	China	201080027763.5	May 3, 2010	Pending		
	Europe	10724898.1	May 3, 2010	Pending	2427188	March 14, 2012
	India	2599/MUMNP/2011	May 3, 2010	Pending		
	Israel	216163	May 3, 2010	Pending		
	Japan	2012509135	May 3, 2010	Pending		
	Mexico	MX/a/2011/011687	May 3, 2010	Pending		
	New Zealand	596861	May 3, 2010	Pending		
	Russia	2011148954	May 3, 2010	Pending		
	South Africa	2011/08894	May 3, 2010	Pending		
	South Korea	Appln no. awaited	May 3, 2010	Pending		
	USA	13/318,235	May 3, 2010	Pending	US 20120046334	February 23, 2012
B. NON-PCT Patent Applications						
	Argentina	20100101501	May 4, 2010	Pending		
	Taiwan	099112188	April 19, 2010	Pending	201039817	November 16, 2010

PATENT

REEL: 028527 FRAME: 0916

SCHEDULE I

A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BREAST CANCER						
Applicant						
PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. PCT Application						
	International Application	PCT/IB2011/055184	November 18, 2011	Pending		
B. Non-PCT Patent Applications						
	Taiwan	100142538	November 21, 2011	Pending		

SCHEDULE I

Title	A COMBINATION OF PACLITAXEL AND A CYCLIN DEPENDENT KINASE (CDK) INHIBITOR FOR THE TREATMENT OF BREAST CANCER					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. PCT Application						
	International Application	PCT/IB2011/055179	November 18, 2011	Pending		
B.Non-PCT Patent Applications						
	Taiwan	100142536	November 21, 2011	Pending		

SCHEDULE I

Title		SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PANCREATIC CANCER				
Applicant		PIRAMAL LIFE SCIENCES LIMITED				
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date

A. PCT Application

International Application	PCT/IB2012/051168	March 13, 2012	Pending	
---------------------------	-------------------	----------------	---------	--

B.Non-PCT Patent Applications

Argentina	20120100840	March 14, 2012	Pending	
Taiwan	101108478	March 13, 2012	Pending	

SCHEDULE I

Title	A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
A. PCT Application						
	International Application	PCT/IB2012/052698	May 30, 2012	Pending		
B.Non-PCT Patent Applications						
	Argentina	Application no. awaited	May 31, 2012	Pending		
	Taiwan	101119157	May 29, 2012	Pending		

SCHEDULE I

Title	COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS						
Applicant	PIRAMAL LIFE SCIENCES LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date	
Priority Patent Application							
	US	61/500,799	June 24, 2011	Pending			

SCHEDULE I

ANTICANCER USE OF CAFFEIC ACID AND DERIVATIVES						
Applicant PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. National Phase Filing In Different Countries Through PCT Route						
	Australia	2007290960	August 20, 2007	Pending	2007290960	April 9, 2009
	Canada	2662126	August 20, 2007	Pending	2662126	
	Europe	07826053.6	August 20, 2007	Granted	EP2061452	October 26, 2011
	India	0515/MUMNP/2009	August 20, 2007	Pending	0515/MUMNP/2009	May 29, 2009
	Israel	197262	August 20, 2007	Pending	197262	December 24, 2009
	Japan	2009-526219	August 20, 2007	Pending	2010502586	January 28, 2010
	USA	12/439,587	August 20, 2007	Pending	US 20100010002	January 14, 2010
B. NON-PCT Patent Applications						
	Taiwan	096131151	August 22, 2007	Pending	200812955	March 16, 2008

SCHEDULE I

Title	PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
National Phase Filing In Different Countries Through PCT Route						
	India	0394/MUMNP/2010	August 6, 2008	Pending	0394/MUMNP/2010	July 30, 2010
	USA	12672485	August 6, 2008	Pending	20110077252	March 31, 2011

SCHEDULE I

Title	[4,5-C] QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
National Phase Filing In Different Countries Through PCT Route						
	Australia	2009349135	June 30, 2009	Pending		
	Canada	2766967	June 30, 2009	Pending		
	Europe	09786482.1	June 30, 2009	Pending		
	India	0229/MUMNP/2012	June 30, 2009	Pending		
	Israel	217303	June 30, 2009	Pending		
	Japan	Application no. awaited	June 30, 2009	Pending		
	New Zealand	597811	June 30, 2009	Pending		
	South Africa	2012/00705	June 30, 2009	Pending		
	USA	13/381,464	June 30, 2009	Pending		

SCHEDULE I

Title	SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. PCT Application						
	International Application	PCT/IB2011/053161	July 15, 2011	Published	WO2012007926	January 19, 2012
B. Non-PCT Patent Application						
	Argentina	20110102555	July 15, 2011	Pending		
	Taiwan	100125119	July 15, 2011	Pending		

SCHEDULE I

Title	SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. PCT Application						
	International Application	PCT/IB2011/055449	December 5, 2011	Pending		
B. Non-PCT Patent Application						
	Argentina	20110104538	December 05, 2011	Pending		
	Taiwan	100144566	December 05, 2011	Pending		

SCHEDULE I

Title	IMIDAZOPYRIDINE DERIVATIVES					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
PCT Application						
National Phase Filing In Different Countries Through PCT Route						
	Australia	Application no. awaited	November 4, 2010	Pending		
	Canada	Application no. awaited	November 4, 2010	Pending		
	Europe	10793313.7	November 4, 2010	Pending		
	India	1384/MUMNP/2012	November 4, 2010	Pending		
	Israel	Application no. awaited	November 4, 2010	Pending		
	Japan	Application no. awaited	November 4, 2010	Pending		
	New Zealand	599856	November 4, 2010	Pending		
	South Africa	Application no. awaited	November 4, 2010	Pending		
	USA	13/508,135	November 4, 2010	Pending		

SCHEDULE I

MACROCYCLIC LACTONE DERIVATIVES FOR THE TREATMENT OF CANCER						
Applicant PIRAMAL LIFE SCIENCES LIMITED AND ONCOTEST GMBH						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
National Phase Filing In Different Countries Through PCT Route						
	Australia	Application no. awaited	November 15, 2010	Pending		
	Brazil	BR 11 2012 011616 9	November 15, 2010	Pending		
	Canada	Application no. awaited	November 15, 2010	Pending		
	China	Application no. awaited	November 15, 2010	Pending		
	Europe	Application no. awaited	November 15, 2010	Pending		
	India	Application no. awaited	November 15, 2010	Pending		
	Israel	Application no. awaited	November 15, 2010	Pending		
	Japan	Application no. awaited	November 15, 2010	Pending		
	Mexico	MX/a/2012/005618	November 15, 2010	Pending		
	New Zealand	600660	November 15, 2010	Pending		
	Russia	Application no. awaited	November 15, 2010	Pending		
	South Africa	Application no. awaited	November 15, 2010	Pending		
	South Korea	Application no. awaited	November 15, 2010	Pending		
	USA	13/510,458	November 15, 2010	Pending		

SCHEDULE I

Title	USE OF MACROCYCLIC LACTONE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS						
Applicant	PIRAMAL LIFE SCIENCES LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date	
National Phase Filing In Different Countries Through PCT Route							
	Australia	Application no. awaited	November 15, 2010	Pending			
	Canada	Application no. awaited	November 15, 2010	Pending			
	Europe	Application no. awaited	November 15, 2010	Pending			
	India	Application no. awaited	November 15, 2010	Pending			
	Israel	219806	November 15, 2010	Pending			
	Japan	Application no. awaited	November 15, 2010	Pending			
	New Zealand	Application no. awaited	November 15, 2010	Pending			
	South Africa	Application no. awaited	November 15, 2010	Pending			
	USA	13/510,552	November 15, 2010	Pending			

SCHEDULE I

HERBAL EXTRACT FOR RENAL DISORDERS						
Applicant						
PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date	
National Phase Filing In Different Countries Through PCT Route						
Australia	2005230727	April 4, 2005	Granted	2005230727	August 25, 2011	
Canada	2555356	April 4, 2005	Pending	2555356	October 20, 2005	
China	200580005190.50	April 4, 2005	Allowed for grant			
Europe	'05718625.6	April 4, 2005	Pending	1732579	September 16, 2009	
Hongkong	'06114084.2	April 4, 2005	Pending	1092387	February 9, 2007	
India	1136/MUMNP/2006	April 4, 2005	Pending	1136/MUMNP/2006	April 6, 2007	
Japan	2007-506899	April 4, 2005	Pending	2007-532527	November 15, 2007	
US	10/591,023	April 4, 2005	Granted	US 7914824	March 29, 2011	

SCHEDULE I

Title	HERBAL COMPOSITION FOR TINEA INFECTION					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
National Phase Filing In Different Countries Through PCT Route						
	Europe	05747216.9	June 17, 2005	Pending	1845785	June 23, 2010
	Georgia	10249/01-2007	June 17, 2005	Granted	P5183	March 25, 2011
	India	1296/MUMNP/2007	June 17, 2005	Granted	251796	April 3, 2012
	Ukraine	2007 09732	June 17, 2005	Granted	85782	February 25, 2009
	US	11/883,599	June 17, 2005	Granted	US 7635493	December 22, 2009

HERBAL COMPOSITION FOR INFLAMMATORY DISORDERS						
Applicant PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. National Phase Filing In Different Countries Through PCT Route						
	Algeria	080271	September 28, 2006	Pending		
	Australia	2006296197	September 28, 2006	Pending	2006296197	June 5, 2008
	Brazil	PI0616724-1	September 28, 2006	Pending	0616724-1	June 28, 2011
	Canada	2624049	September 28, 2006	Pending	2624049	April 5, 2007
	China	200680040770.2	September 28, 2006	Pending	101304756	November 12, 2008
	Europe	06809434.1	September 28, 2006	Pending	1931366	June 18, 2008
	Eurasia	200800850	September 28, 2006	Granted	14070	August 30, 2010
	Georgia	2006 010647	September 28, 2006	Allowed for grant		
	HongKong	08107874.8	September 28, 2006	Pending	1112418	September 5, 2008
	India	0851/MUMNP/2008	September 28, 2006	Granted	251794	April 3, 2012
	Japan	2008-532961	September 28, 2006	Pending	2009510051	March 12, 2009
	Mexico	MX/a/2008/004291	September 28, 2006	Granted	284736	March 15, 2011
	Morocco	30886	September 28, 2006	Granted	29890	October 3, 2008
	South Africa	2008 / 03632	September 28, 2006	Granted	2008 / 03632	November 25, 2009
	Ukraine	200804923	September 28, 2006	Granted	95612	August 25, 2011
B. US Patent Application						
	USA	12/079,853	March 28, 2008	Granted	7,635,494	December 22, 2009
Divisional of US Application No. 12/079,853	USA	12/500,057	July 9, 2009	Allowed for grant		

SCHEDULE I

HERBAL COMPOSITION						
Applicant PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
A. National Phase Filing In Different Countries Through PCT Route						
	Europe	07700543.7	January 5, 2007	Granted	EP 1981517 B	October 19, 2011
	India	1721/MUMNP/2008	January 5, 2007	Pending	1721/MUMNP/2008	December 12, 2008
	USA	12/087,704	January 5, 2007	Granted	US 7862837	January 4, 2011

SCHEDULE I

HERBAL COMPOSITION AND PROCESS FOR ITS PREPARATION						
Applicant PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. Priority Application						
	India	2091/MUM/2006	December 21, 2006	Pending	2091/MUM/2006	August 8, 2008
B. National Phase Filing In Different Countries Through PCT Route						
	Australia	2007337744	February 20, 2007	Pending	2007337744	July 3, 2008
	Canada	2673264	February 20, 2007	Pending	2673264	July 3, 2008
	Europe	07705915.2	February 20, 2007	Pending	2120978	November 25, 2009
	Israel	199433	February 20, 2007	Pending		
	New Zealand	577766	February 20, 2007	Allowed for grant		
	South Africa	2009/04979	February 20, 2007	Pending		
	USA	12/520,198	February 20, 2007	Granted	US 8137708	March 20, 2012

SCHEDULE I

HERBAL COMPOSITION FOR TREATMENT OF INFECTIONS CAUSED BY DERMATOPHYTES						
Applicant PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
A. Priority Application						
	India	478/MUM/2006	March 29, 2006	Granted	249133	October 3, 2011
B. National Phase Filing In Different Countries Through PCT Route						
	Europe	'07735265.6	March 27, 2007	Pending	1998727	December 23, 2009
	USA	12/293300	March 27, 2007	Pending	2009-0104297	April 23, 2009

SCHEDULE I

Title	ORAL HERBAL COMPOSITION FOR THE TREATMENT OF ORAL CANDIDIASIS					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. Priority Application						
	India	1340/MUM/2008	June 25, 2008	Pending	1340/MUM/2008	January 1, 2010
B. National Phase Filing In Different Countries Through PCT Route						
	Algeria	110043	June 25, 2009	Pending		
	Europe	09769770.0	June 25, 2009	Pending	2293806	March 16, 2011
	Georgia	12062/01	June 25, 2009	Pending		
	Ukraine	2011 00413	June 25, 2009	Pending		
	USA	13/001,268	June 25, 2009	Pending	2011/0111067	May 12, 2011
C. Non-PCT Application						
	Argentina	P090102361	June 26, 2009	Pending	72319	August 18, 2010
	Taiwan	098121185	June 24, 2009	Pending	201008573	March 1, 2010
	GCC	13781	June 26, 2009	Pending		
	Panama	88339	June 25, 2009	Granted	88339	October 18, 2010
	Thailand	0901002913	June 26, 2009	Pending		

SCHEDULE I

Title	METHOD FOR EXTRACTING ACTIVE CONSTITUENTS OF OCHROCARPUS LONGIFOLIUS, FORMULATION BASED ON SAID CONSTITUENTS, PROCESS FOR ITS PREPARATION, AND THERAPEUTIC AND COSMETIC USE THEREOF					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. Priority Application						
	India	1292/MUM/2010	April 20, 2010	Pending		
B. Indian Patent Application						
Divisional of 1292/MUM/2010	India	1273/MUM/2011	April 20, 2011	Pending		
Divisional of 1292/MUM/2010	India	1274/MUM/2011	April 20, 2011	Pending		

SCHEDULE I

Title	A METHOD OF TREATMENT FOR ACNE AND AN ANTI-ACNE FORMULATION					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. Priority Application						
	India (Prov)	647/MUM/2012	March 12, 2012	Pending		

SCHEDULE I

PROCESS FOR PREPARATION OF AN HERBAL EXTRACT						
Applicant PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. Priority Application						
	India	246/MUM/2011	January 28, 2011	Pending		
B. PCT Application						
	International Application	PCT/IN2012/000059	January 27, 2012	Pending		

SCHEDULE I

Title						
Applicant						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
A. US Patent Application						
	USA	11/213,396	August 26, 2005	Granted	7,932,294	April 26, 2011
Divisional of US Appln 11/213,396	USA	12/977,838	August 26, 2005	Pending	20110269722	March 11, 2011
Divisional of US Appln 11/213,396	USA	12/977,929	August 26, 2005	Pending	20110269709	March 11, 2011
Divisional of US Appln 11/213,396	USA	12/977,984	August 26, 2005	Pending	20110272486	October 11, 2011
B. National Phase Filing In Different Countries Through PCT Route						
	Australia	2005281359	August 25, 2005	Pending	2005281359	March 16, 2006
	Canada	2577490	August 25, 2005	Pending	2577490	March 16, 2006
	Europe	05781464.2	August 25, 2005	Granted	EP 1789091 B	August 25, 2010
Divisional of EP Appln. 05781464.2	Europe(Div)	09157001	August 25, 2005	Pending	2075011	July 1, 2009
Divisional of EP Appln. 09157001	Europe(Div)	10184577.4	August 25, 2005	Pending	2266625	December 29, 2010
Divisional of EP Appln. 09157001	Europe(Div)	10184535.2	August 25, 2005	Pending	2266622	December 29, 2010

SCHEDULE I

	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
Divisional of EP Appln. 09157001	Europe(Div)	10185353.9	August 25, 2005	Pending	2269657	January 5, 2011
Divisional of EP Appln. 09157001	Europe(Div)	10185414.9	August 25, 2005	Pending	2266625	December 29, 2010
	India	0439/MUMNP/2007	August 25, 2005	Pending	439/MUMNP/2007	July 20, 2007
	Israel	181504	August 25, 2005	Pending	181504	July 4, 2007
	Japan	2007-529100	August 25, 2005	Pending	2008510795	April 10, 2008
	New Zealand	552539	August 25, 2005	Granted	552539	September 5, 2011
	South Africa	2007/01332	August 25, 2005	Granted	2007/01332	December 31, 2008

SCHEDULE I

Title	NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS						
Applicant	PIRAMAL LIFE SCIENCES LIMITED AND APPARAO SATYAM						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date	
A. Priority Application							
	US	13/092,245	April 22, 2011	Pending	US20110263526	October 27, 2011	
B. PCT Application							
	PCT	PCT/IB2011/05175	April 21, 2011	Published	WO2011/132171	October 27, 2011	

SCHEDULE I

Title	PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
National Phase Filing In Different Countries Through PCT Route						
	Australia	2007298539	September 20, 2007	Pending	2007298539	March 27, 2008
	Brazil	PI0717106-4	September 20, 2007	Pending		
	Canada	2,663,901	September 20, 2007	Pending	2,663,901	March 27, 2008
	China	200780039809	September 20, 2007	Pending	101547902	September 30, 2009
	Europe	07826467.8	September 20, 2007	Granted	EP 2094663 B	January 26, 2011
	India	743/MUMNP/2009	September 20, 2007	Pending	743/MUMNP/2009	July 3, 2009
	Israel	197694	September 20, 2007	Pending	197694	December 24, 2009
	Japan	2009-528850	September 20, 2007	Pending	2010504321	February 12, 2010
	Mexico	MX/a/2009/002906	September 20, 2007	Granted	286611	May 17, 2011
	New Zealand	576196	September 20, 2007	Granted	576196	April 2, 2012
	Russia	2009114544	September 20, 2007	Granted	2448093	April 20, 2012
	South Africa	2009/02725	September 20, 2007	Allowed for grant		
	South Korea	10-2009-7008115	September 20, 2007	Pending	20090074775	July 7, 2009
	USA	12/441,802	September 20, 2007	Granted	US 8030324	October 4, 2011
Divisional of US Appln no. 12/441 802	US(Div)	13/222,662	September 20, 2007	Pending	US 20110312970	December 22, 2011

SCHEDULE I

3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS						
Applicant						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. National Phase Filing In Different Countries Through PCT Route						
	Australia	2007298540	September 20, 2007	Pending	2007298540	March 27, 2008
	Brazil	PI0718510-3	September 20, 2007	Pending		
	Canada	2663943	September 20, 2007	Pending	2663943	March 27, 2008
	China	200780039695.20	September 20, 2007	Pending	101547902	September 30, 2009
	Europe	07826468.6	September 20, 2007	Pending	2094687	September 2, 2009
	Hong Kong	10100415.5	September 20, 2007	Pending	1135690	June 11, 2010
	India	764/MUMNP/2009	September 20, 2007	Pending	764/MUMNP/2009	July 3, 2009
	Israel	197695	September 20, 2007	Pending	197695	December 24, 2009
	Japan	2009-528857	September 20, 2007	Pending	2010504322	February 12, 2010
	Mexico	MX/a/2009/002905	September 20, 2007	Pending		
	New Zealand	576197	September 20, 2007	Granted	576197	April 2, 2012
	Russia	2009114545	September 20, 2007	Allowed for grant		
	South Africa	2009/02724	September 20, 2007	Pending	2009/02724	
	South Korea	10-2009-7008116	September 20, 2007	Pending	20090074775	July 7, 2009
	USA	12/441,891	September 20, 2007	Allowed for grant		
B. Non-PCT Application						
	Argentina	P070104184	September 21, 2007	Pending	62940	December 17, 2008
	Taiwan	'096135227	September 20, 2007	Pending	200817634	April 16, 2008

PATENT

REEL: 028527 FRAME: 0944

SCHEDULE I

Title	METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS						
Applicant	PIRAMAL LIFE SCIENCES LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date	
National Phase Filing In Different Countries Through PCT Route							
	Europe	7826471	September 20, 2007	Allowed for grant			
	India	765/MUMNP/2009	September 20, 2007	Pending	765/MUMNP/2009	July 3, 2009	
	USA	12/441,958	September 20, 2007	Pending	US 20090318465	December 24, 2009	

SCHEDULE I

Title	NOVEL BENZOXAZEPINE COMPOUNDS, THEIR PREPARATION AND USE					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
National Phase Filing In Different Countries Through PCT Route						
	Europe	07826942	November 01,2007	Granted	EP 2077846 B	October 12, 2011
	India	1028/MUMNP/2009	November 01,2007	Pending	1028/MUMNP/2009	July 3, 2009
	USA	12/447,809	November 01,2007	Pending	US 20110152247	June 23, 2011

SCHEDULE I

Title	OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. National Phase Filing In Different Countries Through PCT Route						
	India	0585/MUMNP/2011	August 24, 2009	Pending	0585/MUMNP/2011	December 2, 2011
	USA	13/034, 192	August 24, 2009	Pending	US 20110196002	November 8, 2011
B. Non-PCT Application						
	Taiwan	98128431	August 24, 2009	Pending		

SCHEDULE I

Title	CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT - 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
National Phase Filing In Different Countries Through PCT Route						
	Australia	2010316669	November 1, 2010	Pending		
	Brazil	BR 11 2012 010560 4	November 1, 2010	Pending		
	Canada	Application no. awaited	November 1, 2010	Pending		
	China	Application no. awaited	November 1, 2010	Pending		
	Europe	10812904	November 1, 2010	Pending		
	India	1385/MUMNP/2012	November 1, 2010	Pending		
	Israel	Application no. awaited	November 1, 2010	Pending		
	Japan	Application no. awaited	November 1, 2010	Pending		
	New Zealand	599855	November 1, 2010	Pending		
	Russia	Application no. awaited	November 1, 2010	Pending		
	South Africa	Application no. awaited	November 1, 2010	Pending		
	USA	13/505,917	November 1, 2010	Pending		

SCHEDULE I

Title	INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE						
Applicant	PIRAMAL LIFE SCIENCES LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date	
PCT Application							
	International Application	PCT/IB2010/056141	December 30, 2010	Published	WO2011080718	July 7, 2011	

SCHEDULE I

Title	HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. PCT Application						
	International Application	PCT/IB2011/053810	August 31, 2011	Published	WO/2012/029032	March 8, 2012
B. Non-PCT Application						
	Argentina	20110103235	September 3, 2011	Pending		
	Taiwan	100131612	September 2, 2011	Pending		

SCHEDULE I

Title	HERBAL COMPOSITION AND METHOD FOR THE TREATMENT OF VIRAL INFECTION						
Applicant	PIRAMAL LIFE SCIENCES LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date	
A. National Phase Filing In Different Countries Through PCT Route							
	Australia	2009298013	September 23, 2009	Pending	2009298013	April 1, 2010	
	Canada	2738128	September 23, 2009	Pending	2738128	April 1, 2010	
	Europe	'09752472.2	September 23, 2009	Pending	EP2344172	July 20, 2011	
	India	0813/MUMNP/2011	September 23, 2009	Pending	0813/MUMNP/2011	February 10, 2012	
	Japan	2011-528483	September 23, 2009	Pending	2012-503644	February 9, 2012	
	Russia	2011115602	September 23, 2009	Pending			
	South Africa	2011/03090	September 23, 2009	Pending			
	South Korea	10-2011-7009004	September 23, 2009	Pending	10-2011-0057255	May 31, 2011	
	USA	13/120,765	September 23, 2009	Pending	20110177180	July 21, 2011	
B. Non-PCT Application							
	GCC	14336	September 26, 2009	Pending			

SCHEDULE I

Title	ANTIVIRAL COMPOSITION					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
PCT Application						
	International Application	PCT/IB2012/050631	February 13, 2012	Pending		

SCHEDULE I

NOVEL ANTIBACTERIAL COMPOUNDS						
Applicant COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AND PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. National Phase Filing In Different Countries Through PCT Route						
	Australia	2007237861	April 10, 2007	Allowed for grant		
	Brazil	PI0709833-2	April 10, 2007	Pending	PI0709833-2	July 26, 2011
	Canada	2649480	April 10, 2007	Pending	2649480	October 25, 2008
	China	200780013659.9	April 10, 2007	Allowed for grant		
	Europe	07735435	April 10, 2007	Pending	2007735435	January 7, 2009
	HongKong	09104839.8	April 10, 2007	Pending	1126145	August 28, 2009
	Israel	194634	April 10, 2007	Allowed for grant		
	India	2439/MUMNP/2008	April 10, 2007	Pending	2439/MUMNP/2008	February 27, 2009
	Japan	2009-506001	April 10, 2007	Pending	2009-534370	September 24, 2009
	Mexico	MX/a/2008/013381	April 10, 2007	Allowed for grant		
	New Zealand	571636	April 10, 2007	Granted	571636	December 22, 2011
	Russia	2008143525	April 10, 2007	Granted	2444526	March 10, 2012
	South Korea	10-200807028142	April 10, 2007	Pending	10200807028142	March 10, 2012
	South Africa	2008 / 09821	April 10, 2007	Granted	2008/09821	February 24, 2010
	USA	12/226,403 □	April 10, 2007	Granted	US 8003602	August 23, 2011
B. Non-PCT Application						
	Argentina	P070101633	April 17, 2007	Pending	060494	June 18, 2008
	Taiwan	'096111699	April 2, 2007	Pending	200812607	March 16, 2008

SCHEDULE I

ANTIBIOTIC COMPOUNDS						
Applicant PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
National Phase Filing In Different Countries Through PCT Route						
	Australia	2010290872	August 31, 2010	Pending		
	Brazil	BR 11 2012 004643 8	August 31, 2010	Pending		
	Canada	2772742	August 31, 2010	Pending		
	China	Application no. awaited	August 31, 2010	Pending		
	Europe	10763435.4	August 31, 2010	Pending		
	India	0804/MUMNP/2012	August 31, 2010	Pending		
	Israel	218478	August 31, 2010	Pending		
	Japan	Application no. awaited	August 31, 2010	Pending		
	Mexico	MX/a/2012/002619	August 31, 2010	Pending		
	New Zealand	599175	August 31, 2010	Pending		
	Russia	2012112366	August 31, 2010	Pending		
	South Africa	2012/02350	August 31, 2010	Pending		
	South Korea	10-2012-7008552	August 31, 2010	Pending		
	USA	13/393,294	August 31, 2010	Pending		

SCHEDULE I

Title	MICROPARTICLE FORMULATION FOR PULMONARY DRUG DELIVERY OF ANTI-INFECTIVE MOLECULE FOR TREATMENT OF INFECTIOUS DISEASES						
Applicant	PIRAMAL LIFE SCIENCES LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date	
A. PCT Application							
	International Application	PCT/IB2011/053470	August 4, 2011	Published	WO 2012/017405	February 09, 2012	
B. Non-PCT Application							
	Taiwan	100127712	August 4, 2011	Pending			

SCHEDULE I

COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS						
Applicant PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
Priority Patent Application						
	US	61/566,123	December 2, 2011	Pending		

SCHEDULE I

FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR - ALPHA						
Applicant						
PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. National Phase Filing In Different Countries Through PCT Route						
Divisional application of IL application: 183038	Australia	2005303410	November 8, 2005	Granted	2005303410	March 29, 2012
	Canada	2587671	November 8, 2005	Pending	2587671	May 18, 2006
	China	200580042660	November 8, 2005	Granted	200580042660.5	July 27, 2011
	Europe	05801266.7	November 8, 2005	Pending	1812419	August 1, 2007
	Hong Kong	07112043.5	November 8, 2005	Pending	1103738	December 28, 2007
	India	0840/MUMNP/2007	November 8, 2005	Pending	0840/MUMNP/2007	October 12, 2007
	Israel	183038	November 8, 2005	Pending	183038	September 20, 2007
	Israel	210036	November 8, 2005	Pending	210036	February 28, 2011
	Japan	2007-540782	November 8, 2005	Pending	2008519824	June 12, 2008
	Mexico	MX/a/2007/005470	November 8, 2005	Granted	288639	July 25, 2011
	New Zealand	554937	November 8, 2005	Granted	554937	May 9, 2011
	South Africa	2007/03712	November 8, 2005	Granted	2007/03712	June 25, 2008
	South Korea	10-2007-7013140	November 8, 2005	Pending	20070106981	November 6, 2007
Divisional application of US application: 11/667,580	Russia	2007121682	November 8, 2005	Granted	2406724	December 20, 2010
	USA	11/667,580	November 8, 2005	Granted	US 7834052	November 16, 2010
	USA	12/854,745	August 11, 2010	Granted	US 7964631	June 21, 2011

SCHEDULE I

	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
Divisional application of US application: 11/667,580	USA	12/854,761	August 11, 2010	Granted	US 8163730	April 24, 2012
B. Non-PCT Application						
	Argentina	P050104716	November 10, 2005	Pending	56861	October 31, 2007
	Taiwan	094138179	October 31, 2005	Pending		

SCHEDULE I

Title	METHOD OF USE OF EPIREGULIN PROTEIN AND NUCLEIC ACID ENCODING THE SAME IN INFLAMMATORY CONDITIONS						
Applicant	PIRAMAL LIFE SCIENCES LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date	
National Phase Filing In Different Countries Through PCT Route							
	Australia	2007323115	November 19, 2007	Pending	2007323115	May 29, 2008	
	Canada	2669933	November 19, 2007	Pending	2669933	May 29, 2008	
	Europe	07849174.3	November 19, 2007	Granted	EP 2121955 B	December 28, 2011	
	India	1146/MUMNP/2009	November 19, 2007	Pending	1146/MUMNP/2009	June 11, 2010	
	Israel	198676	November 19, 2007	Pending	198676	August 1, 2011	
	New Zealand	577394	November 19, 2007	Allowed for grant			
	South Africa	2009/04313	November 19, 2007	Granted	2009/04313	July 28, 2010	
	USA	12/515492	November 19, 2007	Pending	US 20100168008	July 1, 2010	

SCHEDULE I

Title	TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
National Phase Filing In Different Countries Through PCT Route						
	India	0368/MUMNP/2010	July 25, 2008	Pending	0368/MUMNP/2010	July 16, 2010
	USA	12/670,701	July 25, 2008	Pending	US 20110009396	January 13, 2011

SCHEDULE I

Title	PYRROLIDINE SUBSTITUTED FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS						
Applicant	PIRAMAL LIFE SCIENCES LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date	
PCT Application							
	International Application	PCT/IB2010/050837	February 26, 2010	Published	WO2011104584	September 1, 2011	

SCHEDULE I

Title	CYTOKINE INHIBITORS						
Applicant	PIRAMAL LIFE SCIENCES LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date	
PCT Application							
	International Application	PCT/IB2011/051269	March 25, 2011	Published	WO2011121505	October 6, 2011	

SCHEDULE I

ANTI-INFLAMMATORY COMPOUNDS						
Applicant PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. Priority Application						
	US	13/012,463	January 24, 2011	Pending		
B. PCT Application						
	International Application	PCT/IB2012/050298	January 23, 2012	Pending		

SCHEDULE I

Title	CRYSTALLINE GLUCOSAMINE SULPHATE METAL SALTS AND PROCESS FOR PREPARING THE SAME					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
A. Priority Application						
	India	1087/MUM/2000	December 01, 2000	Granted	246589	March 7, 2011
	Title: CRYSTALLINE GLUCOSAMINE SULPHATE METAL SALTS AND PHARMACEUTICAL COMPOSITION COMPRISING SAID SALTS					
	India	1088/MUM/2000	December 01, 2000	Granted	197881	December 21, 2005
	Title: A PROCESS FOR THE PREPARATION OF CRYSTALLINE GLUCOSAMINE SULPHATE METAL SALTS					
	India	394/MUM/2001	April 26, 2001	Granted	192077	August 17, /2004
	Title: A PROCESS FOR THE PREPARATION OF GLUCOSAMINE SULPHATE METAL SALTS					
B. National Phase Filing In Different Countries Through PCT Route						
	Algeria	030122	December 3, 2001	Granted	3450	September 6, 2005
	Australia	2002217416	December 3, 2001	Granted	2002217416	May 25. 2007
	Brazil	PI 0115801-5	December 3, 2001	Pending		
	Canada	2436925	December 3, 2001	Granted	2436925	October 13, 2008
	China	ZL01819692.6	December 3, 2001	Granted	CN 100351261	November 28, 2007
	CIS (Eurasia)	200300614	December 3, 2001	Granted	006632	February 24, 2006
	Costa Rica	6986	December 3, 2001	Pending		
	Europe	01998306.3	December 3, 2001	Granted	EP 1347986 B	April 13, 2005
	Hungary	P0302154	December 3, 2001	Pending		
	Indonesia	W00200301056	December 3, 2001	Granted	ID0018592	December 28, 2006
	Israel	156100	December 3, 2001	Granted	156100	December 12, 2009
	Japan	2002-545632	December 3, 2001	Granted	4307072	May 15, 2009
	Lithuania	2003 051	December 3, 2001	Granted	5148	July 26, 2004
	Mexico	PA/a/2003/004693	December 3, 2001	Granted	249634	September 28, 2007
	Morocco (Casablanca)	27186	December 3, 2001	Granted	27186	October 17, 2003

SCHEDULE I

Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
New Zealand	526079	December 3, 2001	Granted	526079	November 10, 2005
Norway	2003 2491	December 3, 2001	Granted	324847	December 17, 2007
Philippines	1-2003-500430	December 3, 2001	Granted	1-2003-500430	June 28, 2007
Poland	P 366 386	December 3, 2001	Granted	PL207740 B1	January 31, 2011
Romania	2003-00464	December 3, 2001	Granted	121 738	March 28, 2008
Singapore	200303148-1	December 3, 2001	Granted	97039	November 30, 2006
Slovak	PP 648-2003	December 3, 2001	Granted	285926	September 3, 2007
Slovenia	P2001 20069	December 3, 2001	Granted	21188	November 3, 2003
South Africa	2003/4185	December 3, 2001	Granted	2003/4185	November 24, 2004
South Korea	2003-7007342	December 3, 2001	Granted	10-842400	June 24, 2008
Sri Lanka	13068	December 3, 2001	Granted	13068	January 31, 2005
Ukraine	2003054898/M	December 3, 2001	Granted	N 74600	January 16, 2006
USA	10/433317	December 3, 2001	Granted	US 6812223	November 2, 2004
Uzbekistan	IAP2003 0857	December 3, 2001	Granted	IAP 03253	December 18, 2006
Vietnam	1-2003-00464	December 3, 2001	Granted	5248	October 25, 2005

SCHEDULE I

TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM PROTON EXCHANGE INHIBITORS						
Applicant PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. National Phase Filing In Different Countries Through PCT Route						
	Australia	2005303409	November 8, 2005	Granted	2005303409	March 29, 2012
	Brazil	PI 0516704-3	November 8, 2005	Pending	0516704-3	September 16, 2008
	Canada	2587620	November 8, 2005	Pending	2587620	May 18, 2006
	China	200580042428.10	November 8, 2005	Pending	101076526	November 21, 2007
	Europe	05801218.8	November 8, 2005	Pending	1812420	August 1, 2007
	India	0810/MUMNP/2007	November 8, 2005	Pending	0810/MUMNP/2007	November 14, 2008
	Israel	183086	November 8, 2005	Pending	183086	September 20, 2007
	Japan	2007540781	November 8, 2005	Granted	4921375	February 10, 2012
	Mexico	MX/a/2007/005469	November 8, 2005	Granted	284735	March 15, 2011
	New Zealand	554936	November 8, 2005	Granted	554936	January 8, 2011
	Russia	2007121681	November 8, 2005	Granted	2390521	March 27, 2010
	South Africa	2007/03756	November 8, 2005	Granted	2007/03756	June 25, 2008
	South Korea	10-2007-7012882	November 8, 2005	Pending	20070106980	November 6, 2007
	USA	11/667583	November 8, 2005	Granted	US 7834001	November 16, 2010
Divisional application of US application: 11/667,583.	USA	12/827,277	November 8, 2005	Granted	US 8183234	May 22, 2012
B.Non-PCT Patent Application						
	Argentina	P 05 01 04717	November 10, 2005	Pending	053312	May 2, 2007
	Taiwan	094138178	October 31, 2005	Pending	200614995	May 16, 2006

PATENT

REEL: 028527 FRAME: 0966

SCHEDULE I

FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE						
Applicant PIRAMAL LIFE SCIENCES LIMITED						
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
A. Priority Application						
	India	1054/MUM/2003	October 8, 2003	Granted	IN 213175	December 24, 2007
B. National						
	Europe	EP 04787579.4	September 30, 2004	Pending	EP1677793	July 12, 2006
	USA	10/574,982	September 30, 2004	Granted	US 7759387	July 20, 2010
Divisional application of US application: 10/574,982	USA	12/795,824	September 30, 2004	Granted	US 7964628	June 21, 2011

SCHEDULE I

Title	ANIMAL MODEL, SYSTEM, AND METHOD FOR SCREENING COMPOUNDS FOR ANTITHROMBOTIC AND/OR THROMBOLYTIC ACTIVITY					
Applicant	PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
National Phase Filing In Different Countries Through PCT Route						
	Europe	08719743	March 18, 2008	Pending	EP2139314	June 30, 2010
	India	1959/MUMNP/2009	March 18, 2008	Pending	1959/MUMNP/2009	May 28, 2010
	USA	12/532,009	March 18, 2008	Pending	US 20100034746	February 11, 2010

SCHEDULE I

Title	ALGINATE TUBE DRUG DELIVERY SYSTEM AND METHOD THEREFOR						
Applicant	PIRAMAL LIFE SCIENCES LIMITED AND PIRAMAL HEALTHCARE LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date	
Priority Patent Application							
	US	13/183,598	July 15, 2011	Pending			

SCHEDULE I

Title	HOLLOW POLYMER MICROSPHERES AS THREE-DIMENSIONAL CELL CULTURE MATRIX						
Applicant	PIRAMAL LIFE SCIENCES LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date	
Priority Patent Application							
	US	61/542,332	October 3, 2011	Pending			

SCHEDULE I

Title	METHOD OF DETECTING AND PREDICTING BRONCHODILATORY RESPONSE TO BETA AGONIST						
Applicant	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AND PIRAMAL LIFE SCIENCES LIMITED						
Patent Details							
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date	
A. US Patent Application							
	USA	10/833,270	April 28, 2004	Granted	US 8093004	January 10, 2012	
Divisional of US Appln. No. 10/833,270	USA	12/230,913	September 8, 2008	Pending			
B. National Phase Filing In Different Countries Through PCT Route							
	Australia	2004319074	April 29, 2004	Granted	2004319074	October 7, 2010	
	Canada	2565126	April 29, 2004	Pending			
	China	200480043197.1	April 29, 2004	Allowed for grant			
	Europe	2004730321	April 29, 2004	Allowed for grant			
	India	03929/DELNP/2004	April 29, 2004	Granted	248009	June 9, 2011	
	Japan	2007510133	April 29, 2004	Allowed for grant			
	New Zealand	551169	April 29, 2004	Granted	551169	September 9, 2010	
	South Korea	1020067025062	April 29, 2004	Granted	1009243710000	August 10, 2009	

SCHEDULE I

Title	NOVEL ALLELIC VARIANT OF A CYTOCHROME P-450 GENE ASSOCIATED WITH DRUG METABOLISM					
Applicant	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AND PIRAMAL LIFE SCIENCES LIMITED					
Patent Details						
	Country	Application No.	Filing date	Status	Patent No./Publication No.	Issue Date/Publication date
A. Priority Document						
	India	1295/DEL/2004	July 15, 2004	Granted	246257	February 22, 2011
B. National Phase Filing In Different Countries Through PCT Route						
	Australia	2005264056	July 15, 2005	Granted	2005264056	August 26, 2010
	Europe	2005780136.0	July 15, 2005	Pending		
C. US Patent Application						
Divisional of US Appln no. 11/183,327	USA	13/108,337	May 16, 2011	Allowed for grant		

PATENT

REEL: 028527 FRAME: 0972

SCHEDULE I

Indian Patent Applications						
Applicant: PIRAMAL LIFE SCIENCES LIMITED						
	Title	Application No.	Filing date	Status	Patent No./ Publication No.	Issue Date/ Publication date
1	A method of extracting gum resins using liquids from natural sources	516/MUM/2000	June 2, 2000	Granted	Patent No. 188852	August 29, 2003
2	An improved method of preparing glucosamine hydrochloride	515MUM/2000	June 2, 2000	Granted	Patent No. 188851	August 29, 2003
3	A Process For The Preparation Of Thiazolidinedione Compounds	527/MUM/2000	June 8, 2000	Granted	Patent No. 187209	September 27, 2002